Newswise — A new study from the Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, shows lesions, which can best be seen on MRI scans, could help identify individuals who are more likely to suffer from more rapidly progressing osteoarthritis.
Osteoarthritis is the most common type of arthritis in the UK and can cause the joints to become painful and stiff. Almost any joint can be affected, but it most often causes problems in the knees, hips, and small joints of the hands. It can progress at varying speeds.
The SEKOIA study, a major international osteoarthritis disease-modifying trial, carried out MRI scanning on the knees of 176 men and women over 50 years old. They were then followed up for an average of three years with repeated knee x-rays. Individuals with abnormalities on their MRI scans at the first appointment were compared to those without to examine the effect on disease progression.
Individuals with bone marrow lesions (BMLs) on their MRI scan were found to have osteoarthritis that progressed more rapidly than those that did not. On average, the space within the joint is lost at a rate of 0.15mm per year however the Southampton study shows that, overall, individuals with BMLs had a loss rate that was 0.10mm per year faster than those without BMLs. This may lead to earlier need for joint replacement or other intervention.
BMLs show up on MRI as regions of bone beneath the cartilage with ill-defined high signal and represent areas of bone marrow oedema, fibrosis, and necrosis. The Southampton researchers believe that therapies to target these abnormalities may slow the progression of this disabling joint disease, but further work is required to examine this.
Dr Mark Edwards, Clinical Lecturer in Rheumatology at the MRC Lifecourse Epidemiology Unit, University of Southampton, led the study which has been published in The Journal of Rheumatology.
He comments: “Osteoarthritis causes a significant burden to individuals and the healthcare system as a whole. If we can identify those people who may experience a rapid progression of the disease, this may be of benefit to both physicians and patients. The next step would be to explore the mechanisms through which bone marrow lesions might influence the progression of osteoarthritis and whether this could lead to a novel treatment.”
Professor Cyrus Cooper, Professor of Rheumatology and Director of the MRC Lifecourse Epidemiology Unit, University of Southampton adds: "This study points to the utility of data derived from large randomised controlled trials in deriving predictive models which will facilitate a stratified approach to therapy in knee osteoarthritis, the commonest cause of arthritis worldwide."
1. A copy of the paper entitled: High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study is available from Media Relations upon request or available at http://www.jrheum.org/content/early/2016/01/02/jrheum.150053.full.pdf+html
2. SEKOIA is an international, multicentre, randomised, double-blind, placebo-controlled phase 3 trial in outpatients with knee osteoarthritis mainly in secondary care. This 3-year study was performed in 98 centres in 18 countries. The selection criteria defined eligible patients as Caucasian ambulatory men and women aged ≥50 years with knee osteoarthritis according to American College of Rheumatology criteria, with pain on at least half of the days of the previous month (intensity ≥40 mm on a 100-mm visual analogue scale). On radiography, included patients were Kellgren and Lawrence grade 2 (ie, definite osteophytes and possible narrowing of joint space) or grade 3 (ie, moderate multiple osteophytes, definite narrowing of joint space and some sclerosis, and possible deformity of bone ends), and had joint space width (JSW) of 2.5 to 5 mm with predominant knee osteoarthritis of the medial tibiofemoral compartment.
3. The Medical Research Council is at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers’ money in some of the best medical research in the world across every area of health. Thirty-one MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomised controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms. www.mrc.ac.uk
4. Through world-leading research and enterprise activities, the University of Southampton connects with businesses to create real-world solutions to global issues. Through its educational offering, it works with partners around the world to offer relevant, flexible education, which trains students for jobs not even thought of. This connectivity is what sets Southampton apart from the rest; we make connections and change the world. http://www.southampton.ac.uk/ http://www.southampton.ac.uk/weareconnected#weareconnected
MEDIA CONTACTRegister for reporter access to contact details
The Journal of Rheumatology, Published online before print January 15, 2016